Overview
- Medicare pricing for GLP-1 drugs will be set at $245 per month with a $50 monthly copay for eligible beneficiaries under a CMS pilot expected to start in mid-2026.
- The TrumpRx portal will offer injectable GLP-1s around $350 per month starting by January and is expected to trend to $245 over two years, outside of insurance.
- If approved by the FDA, starter doses of upcoming oral obesity pills from Eli Lilly and Novo Nordisk must launch at about $149 per month across Medicare, Medicaid and TrumpRx.
- Eligibility under the Medicare pilot is limited to defined clinical groups based on BMI and comorbidities, with officials estimating roughly 10% of Medicare enrollees qualify.
- Medicaid programs can opt into the $245 monthly price, most commercially insured patients are not covered by these agreements, and the companies receive three years of tariff relief plus priority regulatory vouchers.